Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 4/20 | 0.31 |
| ▸ | CNR2 | P34972 | 4/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19704336 | 1.00 | KDM4E (0.32) | KDM4EALDH1A1MAPTHTTPLK1 | |
| SCHEMBL19698242 | 0.94 | PLK1 (0.32) | PLK1 | |
| SCHEMBL19698253 | 0.94 | PLK1 (0.32) | PLK1 | |
| SCHEMBL19704143 | 0.92 | KDM4E (0.34) | KDM4EALDH1A1MAPTHTTPLK1 | |
| SCHEMBL19703739 | 0.92 | KDM4E (0.34) | KDM4EALDH1A1MAPTHTTPLK1 | |
| SCHEMBL19704337 | 0.91 | TSHR (0.33) | ALDH1A1MAPTHTTPLK1RAB9A | |
| SCHEMBL19703734 | 0.91 | TSHR (0.33) | ALDH1A1MAPTHTTPLK1RAB9A | |
| SCHEMBL20033312 | 0.90 | ALDH1A1 (0.35) | KDM4EALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL19703943 | 0.89 | PLK1 (0.31) | KDM4EALDH1A1MAPTHTTPLK1 | |
| SCHEMBL19698235 | 0.89 | L3MBTL1 (0.38) | KDM4EALDH1A1MAPTHTTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | KDM4E 4100/4885ALDH1A1 3212/4885MAPT 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.